GSE147708 Evidence of Y Chromosome LncRNAs involved in Radiation Response of Male Non-Small Cell Lung Cancer Cells

Contributors : Ivan Martinez ; Tayvia BrownmillerSeries Type : Expression profiling by arrayOrganism : Homo sapiensNumerous studies have implicated changes in the Y chromosome in male cancers, however few have investigated the biological importance of Y chromosome non-coding RNAs. Here, we demonstrate a group of Y chromosome-expressed long non-coding RNAs (lncRNAs) involved in male non-small cell lung cancer (NSCLC) radiation sensitivity. Radiosensitive male NSCLC cell lines demonstrated a dose-dependent induction of linc-SPRY3-2/3/4 following irradiation, not observed in radioresistant male NSCLC cell lines. Cytogenetics revealed the loss of chromosome Y (LOY) in the radioresistant male NSCLC cell lines. Gain- and loss-of-function experiments indicated that linc-SPRY3-2/3/4 transcripts affect cell viability and apoptosis. UV Cross-linking and Immunoprecipitation (CLIP) and RNA stability assays identify IGF2BP3 as a binding partner for the linc-SPRY3-2/3/4 RNAs which alters the half-life of the anti-apoptotic HMGA2 mRNA as well as the oncogenic c-MYC mRNA. To assess the clinical relevance of these findings, we examined the presence of the Y chromosome in NSCLC tissue microarrays and the expression of linc-SPRY3-2/3/4 in NSCLC RNAseq and microarray data. We observed a negative correlation between the loss of the Y chromosome or linc-SPRY3-2/3/4 and overall survival. Thus, linc-SPRY3-2/3/4 expression and LOY could represent an important marker of radiation therapy in NSCLC.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research

Related Links:

Publication date: Available online 23 May 2020Source: Practical Radiation OncologyAuthor(s): Roman O. Kowalchuk, Michael R. Waters, K. Martin Richardson, Kelly M. Spencer, James M. Larner, C.R. Kersh
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThe uptake of EGFR mutation testing of patients with NSCLC is suboptimal in many parts of the world. Incomplete uptake of testing is fuelled by selective testing referral practices, sample limitations, and funding constraints.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
We evaluated whether pre- and mid-treatment metabolic tumor volume (MTV) predicts per lesion local recurrence (LR) in patients treated with definitive radiation therapy (RT, dose ≥60 Gy) for locally advanced no...
Source: Radiation Oncology - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
The objectives of this retrospective study were: to investigate mortality, morbidity and oncological outcomes of pulmonary resection after induction therapy (IT) for NSCLC in elderly patients. We divided the cohort into two: patients  
Source: General Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
SUMMARY: Treatment options for patients who develop brain metastases secondary to non-small-cell lung cancer have rapidly expanded in recent years. As a key adjunct to surgical and radiation therapy options, systemic therapies are now a critical component of the oncologic management of metastatic CNS disease in many patients with non-small-cell lung cancer. The aim of this review article was to provide a guide for radiologists, outlining the role of systemic therapies in metastatic non-small-cell lung cancer, with a focus on tyrosine kinase inhibitors. The critical role of the blood-brain barrier in the development of syst...
Source: American Journal of Neuroradiology - Category: Radiology Authors: Tags: ADULT BRAIN Source Type: research
Condition:   Non-Small Cell Lung Cancer Interventions:   Radiation: Cyclical Hypofractionated Palliative Radiation (Quad Shot);   Behavioral: EORTC QLQ-C30 questionnaire Sponsor:   Memorial Sloan Kettering Cancer Center Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Stereotactic body radiation therapy (SBRT) and immune check-point inhibition (ICI) are effective and rapidly growing treatment modalities.1,2 A significant number of studies have established the safety of combined SBRT/ICI for both concurrent and sequential treatments.1-5 In spite of encouraging preclinical data vis- à-vis the abscopal potential of SBRT/ICI therapy, randomized evidence of this synergistic effect in clinical trials is lacking. In the PEMBRO-RT trial, which represents the first randomized SBRT/ICI study in PD-L1-unselected pretreated patients with metastatic non-small cell lung cancer, SBRT follo wed ...
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Brief Reports and Opinion Source Type: research
Authors: Liang X, Cheng Y, Yuan Z, Yan Z, Li Q, Huang Y, Feng G Abstract Pulmonary sarcomatoid carcinoma (PSC) is a group of five rare non-small cell lung cancer subtypes. In the present study, the clinical characteristics and outcomes of patients with PSC registered in the Surveillance, Epidemiology and End Results (SEER) database were investigated. For this purpose, data for patients with PSC (n=1,723) who received their initial diagnosis between 1988 and 2016 were collected from the SEER database. Survival analysis was performed using the Kaplan-Meier curves and the log-rank test. Subsequently, multivariate anal...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Condition:   Non-small Cell Lung Cancer Intervention:   Radiation: Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR) Sponsors:   Cancer Trials Ireland;   Prof Fiona Lyng;   Prof Stephen Pennington Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Genetics | Lung Cancer | Non-Small Cell Lung Cancer | Radiation Therapy | Study